Growth hormone treatment enhances nutrition and growth in children with cystic fibrosis receiving enteral nutrition.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

Impaired longitudinal growth and poor weight gain are common and important problems in children with cystic fibrosis.

This study evaluates the hypothesis that adjunctive growth hormone (GH) therapy augments the growth response to nutritional supplementation.

Who Took Part

The abstract describes 18 children taking part.

The age groups tagged for this paper are children.

Measurements included height, weight, pulmonary function, lean tissue mass, bone mineral content, hospitalizations, outpatient antibiotic use, and caloric intake.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nine were randomly assigned to receive 1 year of GH followed by a second year of GH.

What Was Measured

The subject headings attached to it are Blood Glucose, Body Height, Body Mass Index, Bone Density, Cystic Fibrosis, Energy Intake and Enteral Nutrition.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 18 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2005 (The Journal of pediatrics), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.